Tandutinib hydrochloride (MLN518 hydrochloride) is a potent, selective FLT3 inhibitor with an IC50 of 0.22 uM. It also effectively inhibits c-Kit and PDGFR, with IC50 values of 0.17 uM and 0.20 uM, respectively. This compound is clinically applicable for treating acute myelogenous leukemia (AML) and possesses the capability to cross the blood-brain barrier.